Aytu BioScience Short Term Debt Over Time
| AYTU Stock | USD 1.61 0.01 0.62% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Aytu BioScience Performance and Aytu BioScience Correlation. Aytu |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aytu BioScience. If investors know Aytu will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aytu BioScience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.70) | Revenue Per Share 14.627 | Quarterly Revenue Growth (0.41) | Return On Assets (0.01) | Return On Equity (0.47) |
The market value of Aytu BioScience is measured differently than its book value, which is the value of Aytu that is recorded on the company's balance sheet. Investors also form their own opinion of Aytu BioScience's value that differs from its market value or its book value, called intrinsic value, which is Aytu BioScience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aytu BioScience's market value can be influenced by many factors that don't directly affect Aytu BioScience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aytu BioScience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aytu BioScience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aytu BioScience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Short Term Debt Analysis
Compare Aytu BioScience and related stocks such as Aquestive Therapeutics, Evoke Pharma, and Adamis Pharma Short Term Debt Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AQST | 278 K | 38.6 M | 38.6 M | 38.6 M | 38.6 M | 38.6 M | 38.6 M | 340 K | 4.6 M | 3.3 M | 3.3 M | 2.9 M | 19 M | 412 K | 391.4 K |
| EVOK | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 150.4 K | 146.1 K | 138.5 K | 138.5 K | 138.5 K | 138.5 K | 245.9 K | 24.9 K | 258.1 K | 5 M | 5.2 M |
| SBFM | 17 K | 62.5 K | 62.5 K | 12.5 K | 480.1 K | 1.1 M | 237 K | 722.6 K | 662.8 K | 715.6 K | 964.1 K | 1.9 M | 3.8 M | 118.7 K | 112.7 K |
| SXTC | 375.6 K | 375.6 K | 375.6 K | 375.6 K | 375.6 K | 375.6 K | 302.2 K | 385.1 K | 261.2 K | 6.7 M | 37.1 K | 2 M | 3.4 M | 2.4 M | 1.9 M |
| SHPH | 686.4 K | 686.4 K | 686.4 K | 686.4 K | 686.4 K | 686.4 K | 686.4 K | 686.4 K | 686.4 K | 686.4 K | 686.4 K | 916.4 K | 811.1 K | 648.5 K | 612.5 K |
| LFCR | 200 K | 18.7 M | 9.9 M | 6.1 M | 8.4 M | 11.5 M | 7.9 M | 31.9 M | 61.8 M | 93.4 M | 30.6 M | 45.6 M | 142.5 M | 4.9 M | 4.7 M |
| PTPI | 6.7 M | 6.7 M | 6.7 M | 6.7 M | 6.7 M | 6.7 M | 6.7 M | 6.7 M | 6.7 M | 6.7 M | 7.2 M | 125.6 K | 1.2 M | 1.3 M | 1.2 M |
| IRWD | 1 M | 233 K | 261 K | 1.1 M | 12.4 M | 27.6 M | 6.2 M | 4.1 M | 47.6 M | 1.1 M | 6.3 M | 120 M | 6.1 M | 202.7 M | 212.8 M |
| FLGC | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 329 K | 842 K | 2.2 M | 3.5 M | 3.7 M |
| SNOA | 977 K | 1.4 M | 1.3 M | 143 K | 87 K | 114 K | 197 K | 377 K | 463 K | 732 K | 1.1 M | 1.1 M | 943 K | 719 K | 781 K |
| ESPR | 495.5 K | 15.2 M | 15.2 M | 638 K | 638 K | 1.6 M | 1.7 M | 1 M | 454 K | 454 K | 8 M | 12.7 M | 25.1 M | 36.4 M | 38.2 M |
| DERM | 635 K | 635 K | 635 K | 635 K | 635 K | 1.1 M | 3 M | 4.6 M | 83 K | 83 K | 85 K | 5.4 M | 3 M | 3.1 M | 2.6 M |
| AVDL | 400 K | 2.1 M | 3.4 M | 19.3 M | 42.3 M | 434 K | 268 K | 111 K | 106 K | 645 K | 948 K | 1.8 M | 39.6 M | 1.9 M | 1.8 M |
Aytu BioScience and related stocks such as Aquestive Therapeutics, Evoke Pharma, and Adamis Pharma Short Term Debt description
My Equities
My Current Equities and Potential Positions
| Aytu BioScience | AYTU |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Colorado; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.61
Additional Tools for Aytu Stock Analysis
When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.